This is a very compelling argument for AstraZeneca remaining an independent company: http://dealbook.nytimes.com/2014/05/08/a-case-for-rejecting-pfizers-bid-for-astrazeneca/?_php=true&_type=blogs&partner=yahoofinance&_r=0
